Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura

Completed · Not applicable

Conditions studied: Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenic Purpura

In brief

The purpose of this study is to determine how children with a history of severe, chronic Idiopathic Thrombocytopenic Purpura (ITP) who were treated with rituximab might respond to vaccines. Eligible patients are previously or currently enrolled in a study entitled "Open Label, Phase I/II Trial of Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura in Children and Adolescents" and have decided to obtain an inactivated influenza vaccination. These patients will be invited to provide one blood sample prior to vaccination and a second sample following vaccination to quantify immune response to vaccination.

Key facts

Study ID
NCT01713855
Run by
Neufeld, Ellis J, MD, PhD
People needed
10
Starts
2004-10-01
Expected to finish
2006-03-01
Last updated by the study team
2012-10-25

Who can join

Age: 2 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.